Assessment of home infusion program for treating nonlaryngeal hereditary angioedema attacks

摘要

Ecallantide is a plasma kallikrein inhibitor reported to be effective in treating attacks of hereditary angioedema (HAE). Ecallantide had an anaphylaxis rate of 2.7% after subcutaneous administration in clinical trials, and according to the label it must be administered by a health care professional. Therefore, patients need to travel to an urgent care center, emergency department (ED), or physician office for treatment. To circumvent this requirement, which for many patients decreases access to care, a home infusion program was developed. No published data exist regarding the success or safety of such a program for HAE treatment, and a better understanding of the benefits and challenges of this program is essential to improving the care of HAE patients.